You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Research & Development
Appili Therapeutics and Vitalex Biosciences secure NIAID contract for fungal vaccine development for up to USD40m
Login
Username:

Password:


Related Headlines

DATROWAY receives US priority review for first-line metastatic triple negative breast cancer

Lupin launches Dasatinib tablets in US market

Natera submits Signatera CDx PMA to FDA for bladder cancer use

Pharming receives FDA complete response letter for paediatric Joenja application

Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA

Frontage expands early phase clinical research capabilities across US and China

MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA

FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia

Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA

WuXi Biologics collaborates with Sinorda Biomedicine for antibody development

Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE

Glaukos receives FDA approval for repeat administration of iDose TR

Guerbet's contrast agent Elucirem approved by European Commission in children from birth

Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval

Immusoft's ISP-002 receives US FDA Rare Pediatric Disease designation in mucopolysaccharidosis type II

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026